Import of medical goods services | 'Fast-forward' : Anti-cancer drugs cut prices, foreign hospitals landed

Medicine Network May 23 hearing: Anti-cancer drugs cut prices, foreign hospitals landed, and multiple health experiences entered the homes of ordinary people... With the accelerating pace of China's pharmaceutical industry opening to the outside world, new medicines that benefit people are accelerated to market, more foreign capital, Multinational drug companies have settled in China, sharing the huge dividends brought by China's expansion.

Experts pointed out that China’s opening up in the field of medicine is not only committed to satisfying the growing needs of the people for medical services, but also to stimulating domestic companies to benchmark international standards and draw on international experience to boost the high-quality development of the medical industry and satisfy the people for a better life. Needs.

A small pill affects the hearts of millions of patients. It also confirms the opening of China's pharmaceutical industry to the outside world.

Once upon a time, the life-saving drug “Everything” made the patient frequently sigh, “I can't afford it,” “I can't afford it,” and “Haitao” and “Friendship Shopping” led to more drug There is a risk of safety. Today, with the implementation of the zero-tariff policy on anti-cancer drugs, the pace of approval of imported drugs has accelerated, and the 'intestinal obstruction' of upstream and downstream has been opened one by one. The problem of anti-cancer drug use is being speeded up.

——Expanding the import of medicines. More severe patients are no longer looking for drugs.

The zero tariff of anti-cancer drugs is the righteous point in expanding the import of drugs. The reporter's investigation found that after the anti-cancer drug bevacizumab is included in the medical insurance, it still takes about 1 million yuan to inject one course of treatment. One year needs 17.8 million. Yuan, if zero tariffs are landed, it is expected to save patients nearly 7,000 yuan a year in drug costs.

—— The increase in the import of drugs is the approval acceleration for drug regulatory agencies.

According to Li Jinju, responsible person for drug registration of the State Drug Administration, compared with 2014, China approved 19 imported anti-cancer drugs in 2017, an increase of 280%; the average time for the approval of clinical trials of imported anti-cancer drugs was 114 days, shortening 129 days; The average time to approve the listing of imported anti-cancer drugs is 111 days, 309 days shorter.

The zero tariff of anti-cancer drugs is just the starting point. In the future, China's imported drug benefits will continue to be released. It is understood that the Department of Health and Human Resources of the Ministry of Human Resources and Social Security has started negotiating medical insurance against cancer drugs, and is currently studying and formulating a work plan.

'There are many things that are happy recently, such as accelerating the approval of clinical urgently needed drugs, and the State Council's decentralization of Hainan Boao Music City's international medical tourism pioneer area. medical instruments The right of import and export approval, zero tariff on anti-cancer drugs, which will help change the situation that the original imported drugs were listed in China, lagging behind Europe and the United States for five to eight years, and also help foreign investment. hospital To provide patients with high-quality medical services. ' Talking about the opening up of China's medical industry, the founding of Sinochem, the founder of Hejia Home Healthcare, and CEO Li Bijing are deeply impressed.

Li Jingjing first came to China in 1979 and was officially established in 1997. After benefiting from the spring breeze of China’s reform and opening up, Hejia has set up hospitals and clinics in Beishangguang and other cities over the past 20 years, with an average daily service of more than 2,000 people.

'Twenty years ago, 99% of the people who came to visit their families were foreigners and almost no Chinese. Now 60% are Chinese. This reflects that the Chinese people’s consumption levels are constantly increasing. On the other hand, The policy has continued to open. 'Li Bijing said.

The rapid changes in China's medical services are also attracting foreign doctors to come to China. 'China's open policy is very good and does not make foreign doctors feel 'very inconvenient'. ' A Shanghai-based otolaryngology doctor in Shanghai Haihai clinic told reporters Said that the level of medical service management in China has been continuously improved, and the public's medical needs are also growing, so he decided to bring the experience of foreign medical services to China.

With China medicine The pace of opening up to the outside world has been accelerating, and more and more foreign medical institutions have entered China or cooperated with local Chinese medical institutions.

According to data from the National Health Council, as of January this year, China has a total of 60 Sino-foreign joint ventures and cooperative medical institutions, mainly located in Beijing, Tianjin, Shanghai, Jiangsu and other provinces. Foreign investors mainly come from countries such as the United States, Japan and South Korea, and Singapore. area.

The person in charge of the relevant department of the National Health and Sports Commission pointed out that these joint ventures and cooperative medical institutions brought with them international advanced management and service models, and they also provided references for domestic medical institutions.

With the socialism with Chinese characteristics entering a new era, the pharmaceutical industry has also ushered in the period of rapid expansion and industrial upgrading. The corresponding industrial chain of medical and health services is being formed, and the modern pharmaceutical market opening system is being accelerated—

Policy dividends have been released one after another. In Beijing, the “Opinions of the Beijing Municipal People's Government on Expanding Opening-up to Improve the Use of Foreign Capital” has been issued, implemented, and restrictions on foreign investment in key areas such as health care services have been further relaxed.

Multinational drug companies are intensively landing. Pharmaceutical giants such as American Eli Lilly and Company have established drug R&D centers in China. The demand in the Chinese market has become the primary research direction of multinational pharmaceutical companies.

The strong injection of foreign capital. Roche's innovation center built with 863 million yuan investment in Shanghai's Zhangjiang Hi-Tech Park has risen; Internet healthcare enterprise 'Micromedicine' has received US$500 million in financing led by AIA and other companies.... Foreign investors are generally optimistic about the development prospects of the Chinese pharmaceutical market, mobile medical care, wearable devices, long-term health tracking and other multiple business modules are benefiting more people.

From policy welfare landing to industrial transformation and upgrading, one direction is always clear – the door to the opening of China's pharmaceutical sector will not close, it will only grow bigger and bigger. Cai Jiangnan, Director of the Center for Health Management and Policy at China Europe International Business School said that with Central and Supported by medical reform policies in various regions, the shortage of high-quality medical care, and the gradual increase in the level of people’s income, etc., the promotion of foreign medical institutions and the advancement of high-end medical services will be accelerated.